Tests a growth hormone with semaglutide in adults with obesity

Trial details

Who runs it

Shanghai Zhongshan Hospital

Trial code

NCT06863363

Record updated

7 March 2025

Original description

This study aims to evaluate the efficacy and safety of PEG-rhGH Injection combined with Semaglutide Injection versus Semaglutide Injection monotherapy in improving body composition (lean body mass, fat mass, etc.) in non-diabetic obese adults, while also analyzing changes in body weight, blood glucose, and other metabolic parameters.Read full original descriptionShow less

A Multicenter, Randomized, Open-label, Parallel-controlled Clinical Trial Comparing the Efficacy and Safety of PEG-rhGH Injection Combined with Semaglutide Injection Versus Semaglutide Injection Monotherapy in Body Composition of Non-Diabetic Obese Adults

This study aims to evaluate the efficacy and safety of PEG-rhGH Injection combined with Semaglutide Injection versus Semaglutide Injection monotherapy in improving body composition (lean body mass, fat mass, etc.) in non-diabetic obese adults, while also analyzing changes in body weight, blood glucose, and other metabolic parameters.

Inclusion: Age between 18 years (minimum age) and 50 years (maximum age), inclusive; Gender: Male or female, with a ratio of male to female being 2:1; Body Mass Index (BMI) ≥28 kg/m²; No prior use of semaglutide injection or antidiabetic medications; Free Thyroxine (FT4) levels within normal range at screening; Testosterone levels within normal range at screening (males only); No plans for pregnancy from the time of signing the ICF until 2 months after the study ends, willingness to take effective contraceptive measures to prevent pregnancy or causing a partner's pregnancy, and no plans for sperm or egg donation during the study period; Participants must voluntarily agree to and be able to comply with all scheduled visits, treatment plans, laboratory tests, special examinations, neurological assessments, and other trial procedures, and sign a written informed consent form.

Exclusion: Weight change >5.0% in the 12 weeks prior to screening (self-reported); Any of the following: myocardial infarction, stroke, unstable angina requiring hospitalization, or transient ischemic attack within 180 days before screening, classified as NYHA class III or higher; History of diabetes (type 1, type 2, special types, or gestational diabetes) or currently using injectable or oral antidiabetic medications; Proliferative or severe non-proliferative diabetic retinopathy at screening; fundus examination within 90 days before randomization: proliferative retinopathy or macular edema requiring acute treatment; Used growth hormone therapy in the past 6 months; Used any weight loss medications in the past 3 months; previously underwent obesity surgery or planned obesity surgery during the study; Prior history of pituitary mass; Participated in another clinical trial with approved or investigational drugs/devices within 90 days before screening (excluding those who only signed the consent without receiving any intervention); History of allergic reactions to the study drug or similar drugs; Evaluated by the investigator as unable to tolerate subcutaneous injection, such as those undergoing anticoagulant therapy, thrombocytopenia, known bleeding disorders, or idiopathic thrombocytopenic purpura; Planning surgery within 1 year; history of gastrointestinal surgery (excluding polypectomy and appendectomy); Current or past history of malignancy, or currently having nodules with malignant potential such as thyroid nodules with TIRADS grade ≥4; Current or past history of acromegaly; History of pancreatitis, or current acute or chronic pancreatitis; History of cholecystitis, or current gallbladder/biliary disease symptoms, or treatable gallstones or polyps; Family or personal history of multiple endocrine neoplasia type 2 or thyroid cancer (family defined as first-degree relatives); History of seizures; History of substance abuse and/or alcoholism, or mental disorders; during screening, had impaired consciousness including somnolence, stupor, coma, confusion; Questionnaire PHQ-9 score ≥15; history of suicidal behavior; Columbia-Suicide Severity Rating Scale (C-SSRS) question 1 or 2 indicating suicidal ideation (answering "yes" to question 1 or 2); Clinically significant severe ECG abnormalities (e.g., QT prolongation [>450 ms in men, >470 ms in women], ventricular Flutter, ventricular fibrillation, torsades de pointes, sick sinus syndrome, third-degree heart block without pacemaker therapy, and other severe abnormalities as assessed by the investigator), uncontrolled blood pressure despite treatment/untreated (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg during screening, systolic BP <90 mmHg and/or diastolic BP <50 mmHg), or other cardiovascular diseases deemed unsuitable for the study by the investigator; Triglycerides ≥500 mg/dL (5.65 mmol/L); Hemoglobin A1c ≥6.5% during screening; Any of the following laboratory tests at screening: AST or ALT >2.5 ULN; total bilirubin >1.5 ULN; TSH <0.4 or >6 mIU/L; calcitonin >50 ng/L; Serum creatinine >1.5 ULN, eGFR <60 mL/min/1.73 m² [using the modified simplified MDRD equation: eGFR = 175 × (serum creatinine in mg/dL)\^-1.234 × age\^-0.179 × 0.79 for women], or kidney impairment requiring dialysis; IGF-1 SDS >2.0 (age and gender matched); Unable to accept regular follow-up; Those who have difficulty with self-injection; Positive blood HCG during screening; breastfeeding women; postmenopausal women; women with FSH >30 IU/L during screening; Tumor markers during screening: CA125 (for women), CA199, CEA, AFP above upper limit of normal range; PSA above upper limit of normal range (for men); Other reasons for exclusion as deemed by the investigator, such as any situation endangering participant safety or affecting compliance with the protocol.

ClinicalTrials.gov NCT06863363